Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy C Peterson

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanomaAmy C Peterson, Helena Harlin, Thomas F Gajewski
Cancer Immunology, Immunotherapy : CII|February 10, 2006
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascitesHelena Harlin, Todd V Kuna, Amy C Peterson, et al.
European Journal of Immunology|September 30, 2003
T cell development and function in CrkL-deficient miceAmy C Peterson, Reinhard E Marks, Patrick E Fields, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanomaAmy C Peterson, Susan Swiger, Walter M Stadler, et al.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
Cancer Research|February 12, 2004
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cellsChristian Blank, Ian Brown, Amy C Peterson, et al.
Cancer Research|March 19, 2009
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentHelena Harlin, Yuru Meng, Amy C Peterson, et al.
Nature Immunology|October 10, 2006
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alphaYuanyuan Zha, Reinhard Marks, Allen W Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate CancerMichael J Morris, Dana E Rathkopf, William Novotny, et al.
Investigational New Drugs|March 4, 2006
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinomaAmy C Peterson, Helena Harlin, Theodore Karrison, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2003
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanomaAmy C Peterson, Helena Harlin, Thomas F Gajewski
Cancer Immunology, Immunotherapy : CII|February 10, 2006
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascitesHelena Harlin, Todd V Kuna, Amy C Peterson, et al.
European Journal of Immunology|September 30, 2003
T cell development and function in CrkL-deficient miceAmy C Peterson, Reinhard E Marks, Patrick E Fields, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanomaAmy C Peterson, Susan Swiger, Walter M Stadler, et al.
The Prostate|October 24, 2008
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancerDavid Knight, Amy C Peterson, Brian I Rini, et al.
Cancer Research|February 12, 2004
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cellsChristian Blank, Ian Brown, Amy C Peterson, et al.
Cancer Research|March 19, 2009
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentHelena Harlin, Yuru Meng, Amy C Peterson, et al.
Nature Immunology|October 10, 2006
T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alphaYuanyuan Zha, Reinhard Marks, Allen W Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2016
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate CancerMichael J Morris, Dana E Rathkopf, William Novotny, et al.
Investigational New Drugs|March 4, 2006
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinomaAmy C Peterson, Helena Harlin, Theodore Karrison, et al.
Pageof 2